Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

PepGen Q3 2026 Results: Net Loss of $19.4M, Loss Widens

PepGen Inc. is a clinical-stage biotechnology company focused on developing PGN-EDODM1, its lead product candidate. The company remains pre-revenue, reporting significant accumulated losses and a continued need for substantial additional funding to support its research and development programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-19.4-18.0
Net income-19.4-18.0
EPS (diluted, $ a share)$-0.28$-0.52

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PEPG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

PepGen Inc.: key numbers

Share price
$4.19Close, Nov 16
Market cap
$290M
Shares outstanding
69.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from PepGen Inc.

All →
4:34 PM ET 8-K
Capital Raise

PepGen Capital Raise of $125M

PepGen Inc. entered into an underwriting agreement to sell 25,000,000 shares of common stock at a public offering price of $5.00 per share. The company expects to raise approximately $125.0 million in gross proceeds (excluding the underwriters' 30-day option for an additional 3.75 million shares) to fund clinical development and general corporate purposes.

Value
$125M
8:01 AM ET 8-K
Clinical Trial Data

PepGen Clinical Trial Data

PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in patients with myotonic dystrophy type 1. The data demonstrated a mean splicing correction of 46.5%, the highest reported to date in a multiple dose study, alongside functional improvements and a generally well-tolerated safety profile.

“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution. We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”

James McArthur, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.